5%) compared to the control arm (10 2%) [41] However, there is t

5%) compared to the control arm (10.2%) [41]. However, there is the need to follow-up a nonsignificant trend toward an increase rate of miscarriage for pregnancies conceived within 3 months of Cervarix® vaccination. Similarly, in a combined analysis of phase III trials involving Gardasil®, the proportions of women with live births, spontaneous abortions and congenital abnormalities were similar in the vaccine and

control groups [15] and [42]. For example, the rate of spontaneous abortion was 21.9% and 23.3% in the Gardasil® and control groups, respectively. The congenital abnormalities observed were diverse and consistent with those generally seen in young women. Several post-licensure safety studies have been conducted or are ongoing [43], find more [44] and [45]. To date, the findings are consistent with those of the clinical trials. The end of study results (median follow-up of 4 years) of a multi-centric Gardasil® trial in 3819 mid-adult women, ages 24–45, were recently published [46]. The results confirm and extend an interim analysis of this trial in establishing that older women without evidence of prior exposure to

the vaccine types can benefit from the vaccine [47]. In the Pictilisib ic50 ATP population, efficacy against a combined primary endpoint of 6-month persistent infection, CIN of any grade or EGL related to the vaccine types was 88.7% (Table 9). Similar efficacies were observed for CIN, EGL and persistent infection individually. There was a trend Linifanib (ABT-869) for protection against vaccine type CIN2/3 in the ATP analysis, but the study was not powered for

this endpoint and the efficacy was not statistically significant. Vaccine efficacies against these endpoints irrespective of HPV type were not reported. In the case of mid-adult women, ATP and ITT-naïve analyses have limited public health implications, since prescreening women and vaccination of only HPV DNA/seronegatives is not being seriously contemplated. This is in contrast to the trials in young women in which these cohorts provide the best approximation for the primary target for the vaccines, girls prior to the onset of sexual activity. Of more practical relevance, the efficacy for the combined primary endpoint in the ITT population was 47.2% for vaccine-targeted types [46]. From a public health perspective, perhaps the most relevant analysis was the overall vaccine impact on cervical and external genital procedures regardless of HPV type in the ITT population. There were modest non-significant rate reductions in colposcopy, biopsy, and definitive treatment of 6.8, 6.4, and 2.4%, respectively. The safety profile in mid-adult women was similar to that seen in younger women, with a somewhat greater number of Gardasil® vaccinees having adverse injection-site experiences compared to controls (76.7% vs 64.2%).

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>